These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 38433568)

  • 1. Targeting epidermal growth factor receptor and its downstream signaling pathways by natural products: A mechanistic insight.
    Damare R; Engle K; Kumar G
    Phytother Res; 2024 May; 38(5):2406-2447. PubMed ID: 38433568
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural Products Targeting EGFR Signaling Pathways as Potential Anticancer Drugs.
    Wang X; Xu L; Lao Y; Zhang H; Xu H
    Curr Protein Pept Sci; 2018 Feb; 19(4):380-388. PubMed ID: 28059040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HGF induces novel EGFR functions involved in resistance formation to tyrosine kinase inhibitors.
    Gusenbauer S; Vlaicu P; Ullrich A
    Oncogene; 2013 Aug; 32(33):3846-56. PubMed ID: 23045285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent Advances on Epidermal Growth Factor Receptor as a Molecular Target for Breast Cancer Therapeutics.
    Shetty SR; Yeeravalli R; Bera T; Das A
    Anticancer Agents Med Chem; 2021; 21(14):1783-1792. PubMed ID: 33355057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
    Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
    Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
    Zhou Y; Takahashi JI; Sakurai H
    Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
    Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
    Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EGFR-mediated autophagy in tumourigenesis and therapeutic resistance.
    Wu M; Zhang P
    Cancer Lett; 2020 Jan; 469():207-216. PubMed ID: 31639425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. EGFR-TKIs resistance via EGFR-independent signaling pathways.
    Liu Q; Yu S; Zhao W; Qin S; Chu Q; Wu K
    Mol Cancer; 2018 Feb; 17(1):53. PubMed ID: 29455669
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Natural tyrosine kinase inhibitors acting on the epidermal growth factor receptor: Their relevance for cancer therapy.
    Liang Y; Zhang T; Zhang J
    Pharmacol Res; 2020 Nov; 161():105164. PubMed ID: 32846211
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging paradigms and recent progress in targeting ErbB in cancers.
    Stoup N; Liberelle M; Lebègue N; Van Seuningen I
    Trends Pharmacol Sci; 2024 Jun; 45(6):552-576. PubMed ID: 38797570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review on EGFR Inhibitors: Critical Updates.
    Singh D; Attri BK; Gill RK; Bariwal J
    Mini Rev Med Chem; 2016; 16(14):1134-66. PubMed ID: 26996617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Natural Sourced Inhibitors of EGFR, PDGFR, FGFR and VEGFRMediated Signaling Pathways as Potential Anticancer Agents.
    Nandi S; Dey R; Samadder A; Saxena A; Saxena AK
    Curr Med Chem; 2022; 29(2):212-234. PubMed ID: 33655823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Naturally Occurring Compounds as Potential Inhibitors of Epidermal Growth Factor Receptors (EGFRs).
    Oktavia L; Fuad AM; Senjaya SK; Yuliyawati Y
    Comb Chem High Throughput Screen; 2023; 26(6):1093-1107. PubMed ID: 35894461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy.
    Ayati A; Moghimi S; Salarinejad S; Safavi M; Pouramiri B; Foroumadi A
    Bioorg Chem; 2020 Jun; 99():103811. PubMed ID: 32278207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations.
    Wykosky J; Fenton T; Furnari F; Cavenee WK
    Chin J Cancer; 2011 Jan; 30(1):5-12. PubMed ID: 21192840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor as a therapeutic target in glioblastoma.
    Kalman B; Szep E; Garzuly F; Post DE
    Neuromolecular Med; 2013 Jun; 15(2):420-34. PubMed ID: 23575987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. EGFR as a potential target for the treatment of pancreatic cancer: dilemma and controversies.
    Nedaeinia R; Avan A; Manian M; Salehi R; Ghayour-Mobarhan M
    Curr Drug Targets; 2014; 15(14):1293-301. PubMed ID: 25429712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The ErbB/HER family of protein-tyrosine kinases and cancer.
    Roskoski R
    Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.